重药控股(000950.SZ)：预计前三季度净利润同比增长22.51%—36.88%

Core Viewpoint - The company expects a net profit attributable to shareholders of 358 million to 400 million yuan for the first three quarters, representing a year-on-year growth of 22.51% to 36.88% [1] - The net profit after deducting non-recurring gains and losses is projected to be 348 million to 390 million yuan, indicating a year-on-year increase of 25.48% to 40.62% [1] Business Performance - The company's various business segments, including pharmaceuticals, medical devices, traditional Chinese medicine, specialty pharmacies, and emerging businesses, continue to develop steadily [1] - The company is enhancing its network layout and achieving steady growth in operating revenue [1] - Through refined management practices, the company is improving operational efficiency and achieving cost reduction and efficiency enhancement [1]